Related Experiment Video

Updated: Sep 2, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 19, 2013

Are Catechins Natural Tyrosine Kinase Inhibitors?

Agapios Sachinidis, Jurgen Hescheler

    Drug News & Perspectives
    |April 5, 2003
    PubMed

    Insights

    Green tea catechins show potential as natural inhibitors of tyrosine kinase receptors (RTKs), suggesting their use in treating cancer and cardiovascular diseases by targeting RTK activity.

    Area of Science:

    • Biochemistry
    • Pharmacology
    • Oncology

    Background:

    • Enhanced activity of tyrosine kinase receptors (RTKs) is linked to proliferative diseases like cancer and atherosclerosis.
    • Growth factors signaling through RTKs contribute to tumor and cardiovascular disease development.

    Purpose of the Study:

    • To explore the potential of natural compounds as RTK inhibitors.
    • To investigate the role of catechins in inhibiting RTKs and their antiangiogenic properties.

    Main Methods:

    • Review of animal and cell culture studies.
    • Identification of catechins as natural RTK inhibitors.

    Main Results:

    • Catechins, derived from green tea, are identified as potent inhibitors of several RTKs.
    • Evidence suggests catechins possess antiangiogenic properties.

    Conclusions:

    • Catechins demonstrate potential as therapeutic agents for cancer and cardiovascular diseases.
    • Further research into catechins could lead to novel treatments targeting RTK pathways.

    More Related Videos

    Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

    Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

    Published on: September 19, 2018

    Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity09:32

    Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

    Published on: October 17, 2025

    Related Concept Videos

    Inhibition of Cdk Activity02:34

    Inhibition of Cdk Activity

    The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
    M-Cdk Drives Transition Into Mitosis02:15

    M-Cdk Drives Transition Into Mitosis

    Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
    Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
    M cyclin...
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...
    Receptor Tyrosine Kinases01:26

    Receptor Tyrosine Kinases

    Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
    Inhibition of CDK Activity02:34

    Inhibition of CDK Activity

    The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
    Transducer Mechanism: Enzyme-Linked Receptors01:27

    Transducer Mechanism: Enzyme-Linked Receptors

    Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
    Major types that are helpful drug targets include: